SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
Business
AbbVie to Award Shareholders, Increase Employees’ Pay on Rosy 2018 Forecast
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
January 29, 2018
 · 
2 min read
 · 
Mark Terry
Drug Development
The “Magic Word” That Can Trigger a Drugmaker’s Stock to Soar
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
January 8, 2018
 · 
1 min read
Drug Development
AbbVie Scores Key Trial Win for RA Drug With One Fatal Event Reported
AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients.
December 20, 2017
 · 
2 min read
 · 
Alex Keown
Ignyta Stock Booms on Promising Mid-Stage Lung Can
Pharm Country
World’s Top 5 Best-Selling Drugs in 2017
The five top-selling drugs brought in a combined $48B so far this year.
December 18, 2017
 · 
2 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Biotech Bay
Why AbbVie’s Booming 2017 Could Continue in 2018
Now that 2017 is drawing to an end, though, it’s time to focus on the new year.
December 15, 2017
 · 
1 min read
Investor
Genetown
AbbVie, Pfizer Jump in on Newly-Launched Jnana Therapeutics’ $50M Funding Round
Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.
December 14, 2017
 · 
2 min read
 · 
Mark Terry
J&J, Sanofi Top Bioethics International Transparen
Policy
J&J, Sanofi Top Bioethics International Transparency Report
Rounding out the top five companies behind J&J and Sanofi are AbbVie, Celgene and Merck.
December 12, 2017
 · 
4 min read
 · 
Alex Keown
Ignyta Stock Booms on Promising Mid-Stage Lung Can
Drug Development
AbbVie, Genentech’s Venclexta Plus Rituxan Crushes Chemo in Rituxan CLL Study
At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.
December 12, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
AbbVie Touts Late-Stage Psoriasis Drug Trial Data
AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster drug Humira or J&J’s Stelara for psoriasis patients.
October 26, 2017
 · 
2 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Deals
AbbVie Declares Quarterly Dividend Payable on August 15, 2019
June 20, 2019
 · 
1 min read
BioForest
EndBrainCancer Initiative Announced Campaign for New Brain Cancer Clinical Trials in the Greater Puget Sound Area at its Education, Awareness & Action Dinner
June 13, 2019
 · 
2 min read
Drug Development
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR
June 12, 2019
 · 
10 min read
Drug Development
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
June 11, 2019
 · 
8 min read
BioMidwest
AbbVie to Present at the Goldman Sachs Global Healthcare Conference
June 7, 2019
 · 
2 min read
Drug Development
IBRUVICA Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab
June 4, 2019
 · 
16 min read
FDA
AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®)
June 4, 2019
 · 
14 min read
BioMidwest
AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
June 4, 2019
 · 
17 min read
BioMidwest
AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings
May 30, 2019
 · 
32 min read
Drug Development
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
May 17, 2019
 · 
5 min read
Load More